What is Zacks Research’s Estimate for LEXX FY2028 Earnings?

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at Zacks Research issued their FY2028 earnings per share estimates for shares of Lexaria Bioscience in a research report issued to clients and investors on Tuesday, February 10th. Zacks Research analyst J. Vandermosten anticipates that the company will post earnings per share of ($0.28) for the year. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share.

Lexaria Bioscience (NASDAQ:LEXX) last released its earnings results on Tuesday, January 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Lexaria Bioscience had a negative return on equity of 226.58% and a negative net margin of 1,685.84%.The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.14 million.

LEXX has been the subject of a number of other research reports. HC Wainwright decreased their price objective on shares of Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating for the company in a report on Friday, December 26th. Wall Street Zen cut shares of Lexaria Bioscience from a “hold” rating to a “sell” rating in a research report on Sunday, December 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Lexaria Bioscience in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $1.50.

Lexaria Bioscience Price Performance

Shares of LEXX stock opened at $0.68 on Wednesday. The stock has a market cap of $16.97 million, a PE ratio of -1.22 and a beta of 0.56. The stock has a 50-day moving average of $0.78 and a 200-day moving average of $0.92. Lexaria Bioscience has a one year low of $0.46 and a one year high of $1.90.

Institutional Investors Weigh In On Lexaria Bioscience

Several large investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in shares of Lexaria Bioscience by 25.7% during the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after acquiring an additional 44,939 shares during the period. Byrne Asset Management LLC boosted its stake in Lexaria Bioscience by 236.8% in the 4th quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after purchasing an additional 74,180 shares during the period. Finally, Virtu Financial LLC bought a new position in Lexaria Bioscience during the 3rd quarter worth about $28,000. Institutional investors own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.